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Abstract: Tryptophan and tyrosine metabolism has a major effect on human health, and disorders
have been associated with the development of several pathologies. Recently, gut microbial metabolism
was found to be important for maintaining correct physiology. Here, we describe the development
and validation of a UHPLC-ESI-MS/MS method for targeted quantification of 39 metabolites related
to tryptophan and tyrosine metabolism, branched chain amino acids and gut-derived metabolites
in human plasma and urine. Extraction from plasma was optimised using 96-well plates, shown to
be effective in removing phospholipids. Urine was filtered and diluted ten-fold. Metabolites were
separated with reverse phase chromatography and detected using triple quadrupole MS. Linear
ranges (from ppb to ppm) and correlation coefficients (r2 > 0.990) were established for both matrices
independently and the method was shown to be linear for all tested metabolites. At medium spiked
concentration, recovery was over 80% in both matrices, while analytical precision was excellent
(CV < 15%). Matrix effects were minimal and retention time stability was excellent. The applicability
of the methods was tested on biological samples, and metabolite concentrations were found to be in
agreement with available data. The method allows the analysis of up to 96 samples per day and was
demonstrated to be stable for up to three weeks from acquisition.
Keywords: tryptophan metabolism; tyrosine metabolism; branched chain amino acids; gut microbiota
metabolites; targeted metabolomics; LC-MS/MS; human plasma; urine; clinical studies
1. Introduction
The emerging field of “nutrition-microbiome-human health” has raised many unanswered
questions regarding the complex relationship and interplay of gut microbiota, their metabolites in
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homeostasis and human physiology. Results from epidemiological studies, clinical trials and recent
meta-analyses have supported the link between mood disorders, obesity and gut microbiota [1–3],
and recent data have strikingly indicated that emotional stress, anxiety and depression may influence the
development of gastrointestinal disorders and cancer [4–8]; however, the relationship between them is
still unclear. It has been suggested that gut microbial metabolites act on the gut epithelium, modulating
downstream signalling pathways involved in the control of digestion, metabolism, immunity, the brain
and pain [9–13].
Indeed, during the last few years, the link between gut microbiota and the brain has been
investigated in depth [3,14–16], demonstrating that depression is associated with decreased gut
microbiota richness and diversity [17]. The concept of the “brain-gut-microbiome axis” has recently been
introduced to describe the complex interactions between gut microbiota and human physiology [18].
Tryptophan (TRP) metabolism has claimed to be a key player in neurophysiology and
depression [14,17–20], regulation of immune response and inflammation, inflammatory bowel
diseases [21], metabolic syndrome and obesity [18]. TRP is an essential amino acid bearing an
indole group critical for protein synthesis, but it also serves as a substrate for the generation of several
bioactive compounds. In mammals, about 95% of ingested TRP is catabolised through the kynurenine
pathway (KP) [20,22,23] into a range of metabolites known to be involved in inflammation, immune
response and excitatory neurotransmissions [22,24] (Figure 1). Kynurenine (KYN) and its metabolites
are known for their beneficial effects on the central nervous system [20].
Minor pathways of TRP degradation lead to synthesis of the neurotransmitter serotonin (5-HT)
via the hydroxylation pathway, tryptamine (TRY) via decarboxylation and indole-3-pyruvic acid via
transamination pathways [11,23]. Several bacteria have the ability to synthesize 5-HT from dietary TRP,
and are therefore able to modulate the brain-gut axis [25]. Gut microbiota can also produce indole and
its derivatives, such as indole-3-propionic acid (IPA), indole-3-lactic acid (ILA) and indole-3-aldehyde
(IALD) [26]. Indole is synthesized from TRP via the tryptophanase enzyme and this metabolite is able
to maintain host-microbe homeostasis on the mucosal surface [26–28]. Hepatic sulfonation of indole
leads to the production of indoxyl sulfate (IS), a cytotoxic metabolite that induces renal and vascular
dysfunction [29,30]. IPA is a potent antioxidant able to reduce DNA damage and lipid peroxidation,
and to maintain mucosal homeostasis and intestinal barrier functions [31,32]. Clostridium sporogenes
is the predominant IPA producer, but a recent work demonstrated that four other gut bacteria can
synthesize it: Peptostreptococcus anaerobius CC14N and three strains of Clostridium cadaveris [33]. ILA is
an intermediate of IPA production from TRP operated by C. sporogenes, but it is also produced by
Bifidobacterium spp [34]. ILA was also identified as a potential biomarker for alcohol-induced liver
disease in Ppara mouse model [35]. IALD is produced from bacteria belonging to the Lactobacillus
genera and helps to maintain host-microbial homeostasis [36].
The importance of qualitatively and quantitatively understanding gut microbiota regulation of
TRP metabolism in healthy and diseased conditions thus appears to be clear. On the other hand,
emerging evidence has also shown that different concentrations in human biofluids (blood and urine)
and tissues of branched chain amino acids (BCAAs), such as L-methionine (MET), L-valine (VAL),
L-isoleucine (ILE) and L-leucine (LEU) among others, might play an unrecognised and crucial role
in the development of intestinal health [37,38], depression [39] and cancer [40]. In the light of these
facts, it is clear that there is a complex inter-kingdom regulatory network and interactions occurring
between the host, microbiome, and diet.
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Figure 1. Principal branches of the TRP and TYR metabolic pathways covered in this analytical method and structures of the main BCAAs. Red circles represent the 
metabolites detected in plasma, orange circles those detected in urine. The size of the circle is proportional to the median concentration in each biofluid.  : metabolite 
with median concentration of < 1 μM; : metabolite with median concentration of 1 < x < 10 μM; : metabolite with median concentration of > 10 μM.
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Accurate quantitation of TRP derived metabolites and BCAAs in plasma, serum and urine is
becoming increasingly important, since subtle changes may be responsible for mechanistic responses.
However, to date the development and validation of a single robust targeted method providing broad
coverage and suitable for the main biofluids is still lacking. More frequently, only a few metabolites
related to KP have been monitored [41–48]. Zhu and colleagues reported on the quantitation of
19 metabolites in urine and human serum, including microbial derived metabolites [49]. One main
drawback of this method, which could limit applicability in clinical studies requiring the inclusion
of a large number of samples, is the number of laborious steps proposed for metabolite extraction,
which requires the use of single tubes, 1 h incubation at −20 ◦C to ensure protein precipitation and
three centrifugation steps.
In 2016, Marcos and co-workers proposed a method for quantitation of 17 TRP metabolites and
BCAAs in urine and plasma [50]. Again, the procedure for extraction of metabolites from plasma
limited the processing of a large sample set. More recently, Whiley and colleagues (2019) published a
thoroughly validated method for the quantitation of 18 TRP metabolites in serum and plasma based on
Phenomenex PHREE SPE 96-well plate extraction that allows high-throughput sample preparation [51].
The study, which to our knowledge represents the state-of-the-art in the field, covers the quantitative
analysis of 18 metabolites associated with KP and 5-HT degradation pathways, but did not cover
BCAAs or gut-derived metabolites.
Here, we present a validated analytical method for the simultaneous separation and detection
of 39 metabolites in both plasma and urine using Ultra High Performance Liquid Chromatography-
ElectroSpray-Ionization-Tandem Mass Spectrometry (UHPLC-ESI-MS/MS). Preliminary application
of this method in two independent epidemiological studies across the lifespan of the DOrtmund
Nutritional and Anthropometric Longitudinally Designed (DONALD) Study and the Rhineland Study
allowed us to establish the typical ranges for these 39 metabolites present in the human biofluids of
two German populations.
Legend: TRP: L-tryptophan; KYN: kynurenine; KA: kynurenic acid; 3-OH-KYN: 3-hydroxy
kynurenine; 3-OH-AA: 3-hydroxy-anthranilic acid; AA: anthranilic acid; XA: xanthurenic acid;
QA: quinolinic acid; PA: picolinic acid; 2-AM: 2-aminophenol; 5-OH-TRP: 5-hydroxy-L-tryptophan;
5-HT: serotonin; 5-OH-IAA: 5-hydroxyindole-3-acetic acid; 5-ME-IAA: 5-methoxyindole-3-acetic
acid; NA-5-HT: N-acetyl-5-hydroxytryptamine; MEL: melatonin; 5-ME-TRY: 5-methoxytryptamine;
TRY: tryptamine; IACN: indole-3-acetonitrile; IAA: indole-3-acetic acid; IACT: indole-3-acetamide;
ILA: indole-3-lactic acid; IPA: indole-3-propionic acid; IALD: indole-3-carboxaldehyde; IS: indoxyl
sulfate; NAC: 1-acetylisatin; ICA: indole-3-carboxylic acid; TRPME: tryptophan methyl ester; PHE:
phenylalanine; TYR: tyrosine; TYRA: tyramine; DA: dopamine; 3-ME-TYRA: 3-methoxy-p-tyramine;
DOPAC: 3,4-dihydroxyphenyl acetic acid; HVA: homovanillic acid; GABA: gamma-aminobutyric acid;
ILE: L-isoleucine; LEU: L-leucine; VAL: L-valine; MET: L-methionine.
2. Results
2.1. Liquid Chromatography and Mass Spectrometry
Two Multiple Reaction Monitoring (MRM) transitions were optimised for each target compound
by changing Collision Energy (CE) and Cone Voltage (CV). The one displaying the highest intensity
was selected as the quantifier ion (Q), while the less intense one was selected as the qualifier ion (q).
MS parameters and retention times (RT) are reported in Table 1.
Metabolites 2019, 9, 261 5 of 24
Table 1. Internal standard used for quantification, RT (min) and MS parameters (parent m/z, polarity,
quantifier and qualifier ions m/z, CV and CE) for the selected analytes. A Waters ACQUITY HSST3
(1.8 µm, 2.1 × 150 mm) column was used for metabolite separation.
Metabolite InternalStandard
RT
(min)
Parent
m/z ESI
Q
m/z
q
m/z
CV
(V)
CE
(eV)
γ-aminobutyric acid MET-d4 1.16 104.03 + 68.95 86.14 12 14
l-valine MET-d4 1.47 118.03 + 55.01 72.02 12 18
picolinic acid MET-d4 1.53 124.00 + 77.96 105.87 26 10
dopamine-d4 1.66 158.16 + 94.85 122.4 12 22
dopamine DA-d4 1.67 154.22 + 91.02 119.01 12 20
methionine-d4 1.68 154.09 + 59.17 62.95 12 16
methionine MET-d4 1.68 150.22 + 104.02 56.04 12 10
2-aminophenol TRP-d5 1.70 110.16 + 92.00 65.01 20 14
quinolinic acid MET-d4 1.80 168.22 + 77.98 106.03 14 16
3-hydroxykynurenine TRP-d5 2.01 225.176 + 110.02 162.01 14 18
tyrosine-d4 2.04 186.16 + 140.11 93.95 12 14
tyrosine TYR-d4 2.07 182.17 + 136.07 90.96 18 16
l-isoleucine MET-d4 2.25 132.09 + 86.00 69.00 10 12
tyramine TYR-d4 2.25 138.12 + 76.68 103.97 10 24
l-leucine MET-d4 2.38 132.09 + 86.00 43.00 10 12
serotonin-d4 2.93 181.16 + 118.14 146.05 12 26
serotonin 5-HT-d4 3.02 177.22 + 115.09 132.18 10 26
5-hydroxy-tryptophan TRP-d5 3.00 221.29 + 162.01 134.02 12 18
3-methoxy-p-tyramine TYR-d4 3.02 168.22 + 91.00 119.05 8 20
kynurenine TRP-d5 3.53 209.12 + 94.01 146.08 14 16
dl-phenylalanine TYR-d4 3.61 166.22 + 120.10 103.01 14 20
3-hydroxyanthranilic acid TRP-d5 4.75 154.22 + 80.01 108.01 10 22
tryptophan-d5 4.90 210.16 + 150.09 122.11 12 18
tryptophan TRP-d5 4.94 205.29 + 146.06 118.01 12 16
1-acetylisatin TRP-d5 4.94 190.01 + 148.01 162.01 18 10
DOPAC-d5 4.99 172.11 - 128.04 99.99 14 8
3,4-dihydroxyphenyl acetic
acid DOPAC-d5 5.04 167.07 - 123.05 94.99 14 8
xanthurenic acid TRP-d5 5.03 206.09 + 160.00 132.02 20 18
kynurenic acid-d5 5.41 195.09 + 149.06 121.08 24 18
kynurenic acid KA-d5 5.44 190.09 + 143.99 116.00 20 20
tryptamine TRP-d5 5.45 161.13 + 127.20 117.40 12 24
5-methoxytryptamine TRP-d5 5.60 191.20 + 159.09 143.08 12 22
5-hydroxyindole acetic acid-d5 5.71 197.16 + 150.16 122.17 16 14
5-hydroxyindole acetic acid 5-OH-IAA-d5
5.74 192.23 + 146.27 91.00 18 14
N-acetyl-5-hydroxytryptamine TRP-d5 5.86 219.20 + 160.07 115.09 16 16
tryptophan methyl ester TRP-d5 6.07 219.14 + 160.00 132.02 12 18
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Table 1. Cont.
Metabolite InternalStandard
RT
(min)
Parent
m/z ESI
Q
m/z
q
m/z
CV
(V)
CE
(eV)
homovanillic acid DOPAC-d5 6.20 181.09 - 137.08 121.99 8 10
indoxyl sulfate TRP-d5 6.24 212.04 - 80.08 132.02 24 20
indole-3-acetamide TRP-d5 6.53 175.05 + 102.99 76.95 14 30
anthranilic acid TRP-d5 6.78 138.22 + 91.99 65.04 10 22
indole-3-lactic acid TRP-d5 6.96 206.11 + 160.09 130.02 18 10
indole-3-carboxylic acid TRP-d5 7.15 162.08 + 116.03 88.95 16 20
melatonin TRP-d5 7.31 233.22 + 174.08 159.05 16 14
5-methoxyindole acetic acid TRP-d5 7.35 206.17 + 160.17 145.05 16 16
indole-3-carboxaldehyde TRP-d5 7.36 146.09 + 118.05 90.97 22 24
indole-3-acetonitrile TRP-d5 7.52 130.22 + 76.95 102.99 30 22
indole-3-acetic acid TRP-d5 7.53 176.09 + 130.00 102.99 18 12
indole-3-propionic acid TRP-d5 8.06 190.11 + 130.02 54.96 12 16
With our chromatographic setup, GABA was practically non-retained and eluted with the
chromatographic front. The 150 mm column enabled separation of ILE from LEU, as highlighted
in Figure 2 for the BEH (panel A) and HSST3 (B) columns. The HSST3 column provided baseline
separation of ILE (RT: 2.25 min) from LEU (RT: 2.38 min).
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ff
ithin 8.5 min. The otal run time, including column re-equilibration, was 14 min.
This made it possible to acquire up to 96 sampl s (one 96-well plate) in 24 h. Directing flow waste
during non-acqu sition time enabled us to acquire up to 300 amples per batch without significant
signal l sses for both matrices.
2.2. Linearity and Limit of Quantification (LOQ)
The linearity range for each metabolite was established by using calibration curves in water with
0.1% formic acid (FA), since it was impossible to obtain analyte-free matrices (blanks). Linearity ranges
covered 4+ orders of magnitude, from a few ppb to ppm. The availability of a large number of samples
obtained from two independent German observational and epidemiological studies across the lifespan
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allowed us to finely tune calibration. Working calibration ranges were specifically designed for each
metabolite, to cover the expected concentrations in plasma and urine. All working calibration curves
were found to have a good correlation coefficient (r2 > 0.990) in the tested ranges for both plasma and
urine (see Table S1).
Metabolites at low concentration levels were linear in the range 1–250 ng/mL. By contrast, for high
level metabolites, the upper quantification point was 12500 ng/mL, and above this the MS response
was no longer linear. The exceptions were 3-hydroxykynurenine (3-OH-KYN) in urine, which was
linear between 15–25,600 ng/mL, and homovanillic acid (HVA) in plasma, which was linear in the
range of 156–25,000 ng/mL.
LOQs were in the order of a few ng/mL for low level metabolites, except for 2-aminophenol (2-AM)
(78.1 ng/mL) and 3-hydroxyanthranilic acid (3-OH-AA) (31.2 ng/mL) in plasma, indole-3-acetonitrile
(IACN) in urine (19.5 mg/mL) and 3-OH-KYN in both matrices (31.2 and 15.6 ng/mL in plasma and urine
respectively). For high level metabolites, the LOQ was set as the lowest calibration point. Metabolites
detected in negative ion mode (HVA, DOPAC and IS) displayed higher LOQs in both matrices.
2.3. Retention Time Stability
For both matrices, metabolite RT stability was addressed over a period of three weeks. Most of
the metabolites showed a coefficient of variation lower than 1%, except for 2-AM (CV%: 2.10) and
TYR-d4 (CV% 1.04) in plasma, and IS (CV% 1.09) in urine. See Table S1 for details on plasma and
urine respectively.
2.4. Matrix Effects
Matrix effects (ME), evaluated with the matrix match calibration (MMC) approach, were minimal
and in the range of 80–120% for most metabolites in both plasma and urine (Table S1). Ion suppression
by the matrix component significantly affected quantification of the most polar metabolites: VAL,
dopamine (DA), MET, and quinolinic acid (QA) were suppressed both in plasma and urine, while
2-AM and tyramine (TYRA) were affected only in urine. Quantification of GABA was significantly
deviated in both matrices due to its poor retention with a C18 analytical column.
2.5. Recovery, Intra- and Inter-Day Accuracy and Precision
At medium spiked concentration, metabolite recovery from plasma was over 85%, except for VAL
(80.7%) and picolinic acid (PA) (82.8%). At low spiked concentration, recovery was over 80% for all
metabolites except GABA (71.2%) and QA (76.5%). In urine, recovery at medium spiked concentration
was over 80% for all metabolites. At low spiked concentration, several metabolites, such as DA, ILE,
LEU, TYRA and 3-OH-KYN, had lower recovery, due to the fact that spiked values were close to the
LOQ, so analytical error was greater. Recovery at the highest spiked concentration was slightly over
80% for all metabolites, except 3-OH-AA in urine and GABA in both matrices. All information on
plasma and urine can be found in Table S2.
Accuracy at medium spiked concentration was excellent for all metabolites (CV<15%) in both
plasma and urine (Table S2). At low concentrations, precision was lower than 20% for all metabolites
in plasma, except for PA, 3-OH-KYN, 3-methoxy-p-tyramine (3-ME-TYRA), 3-OH-AA, DOPAC,
5-methoxytryptamine (5-ME-TRY), 5-hydroxyindole-acetic acid (5-OH-IAA) and TRP- methyl ester
(TRPME). Accuracy at low spiked concentration was not calculated for the internal standard. At the
highest concentration, accuracy was low for VAL in plasma and PHE, TYR, 3-OH-AA and TRP in urine.
This was due to the fact that spiked amounts were above the detector linear response. Accuracy was
unsatisfactory for GABA at all concentration levels and was not reported. We propose to use data on
GABA to detect fold changes rather than to provide accurate quantitative data.
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2.6. Carryover Effect and Phospholipid Removal
No carryover effect was observed within and between runs for either plasma or urine. Figure 3
shows the MRM transition of TRP (205.29 > 146.06; RT: 4.95 min) for a plasma sample spiked at the
highest concentration (25,000 ng/mL) (panel A) and the blank, after the acquisition of 5 plasma samples
spiked at the highest concentration (B). Similarly, (C) shows the MRM transition of kynurenic acid (KA)
(190.09 > 149.99; RT: 5.45 min) at the highest calibration point, while (D) shows the MRM acquired in
the following run after injection of acetonitrile (ACN). Column cleaning for 3 min at 100% B ensured
complete elution of the tested metabolites, while the strong wash solvent ensured good needle cleaning.
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Figure 3. MRM of TRP (205.29 > 146.06) after injection of a plasma sample spiked at the highest
concentration (panel A) and injection of ACN at the end of the entire batch (n = 5) (B). MRM of KA
(190.09 > 143.99) at the highest point of calibration (C) and in the following run after injection of
ACN (D).
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Biological samples, particularly plasma, contain significant amounts of phospholipids, mainly
phosphatidylcholine (PC), phosphatidylethanolamine (PE) and sphingomyelin (SM). All these matrix
components can significantly affect compound ionization through ion enhancement/suppression effects.
With our chromatographic setup, phospholipids eluted after 8.50 min, therefore well after the last
eluting metabolite (IPA, RT: 8.06 min). Nevertheless, Ostro 96-well plates were also able to efficiently
remove phospholipids from plasma, as demonstrated by the Precursor Ion Scan (PIS) of m/z 184.03 on
crude plasma (Figure 4A) or plasma after sample clean up (B). Urine contained traces of PC and SM
and 10-fold dilution did not affect the MS response (data not shown).Metabolites 2019, 9, x FOR PEER REVIEW 9 of 23 
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2.7. Method Application to Biological Samples
To demonstrate the applicability of the method, we analysed fasting samples of plasma (n = 1000)
and 24-h urine samples (n = 672) from two independent populations. As the Rhineland Study did not
collect 24-h uri e and the DONALD study did not collect blood, no paired samples were available from
the same individual. Sa les were pseudonymise and ra domised prior to extraction, and were
extracted independently. Biological QCs were prepared by mixing equal volumes of sample. T enty
QCs were injected at the beginning of the acquisition sequence in order to stabilise the MS response
and at intervals of 15 samples across the sequence in order to test MS stability. Calibration curves were
acquired after the first 20 QCs, approximately every 300 samples, and at the end of each batch.
The method allowed quantification of 24 metabolites in plasma and 30 metabolites in urine:
23 metabolites were common to the two matrices; DOPAC was detected exclusively in plasma, while
8 metabolites were found exclusively in urine (Figure 5). The metabolites in our study resulting
unique to urine were the neurotransmitter TYRA, the metabolite from methylation of DA, 3-ME-TYRA,
the immediate precursor of 5-HT, 5-OH-TRP, the highly reactive neurotoxin 3-OH-KYN and the uremic
toxin AA in the KP, as well as the β-arylamine neurotransmitter and microbial catabolite TRY and the
intermediate of the indole-3-acetic acid (IAA) pathway indole-3-acetamide (IACT) (Figure 1).
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(8) and in both matrices (23).
The minimum, median and maximum values detected in both matrices for the two German
populations are reported in Table 2. Qualitatively, here we divided the metabolites into three categories
according to the median value: low (median < 1 µM), medium (median 1< × <10) and high (median >
10) level metabolites (Figure 6). In general, high level metabolites in plasma (VAL, ILE, LEU, MET,
TYR, PHE and TRP) were also present in high concentrations in urine. Medium level metabolites (QA,
KYN, IACN and IAA) were detected in higher concentrations in urine, except for IPA, which was
found at a lower concentration. Of the low level metabolites in plasma, XA, KA, 5-OH-IAA and HVA
were those excreted at the highest concentrations in urine. As expected, indole-3-carbocylic acid (ICA)
was detected only in urine.Metabolites 2019, 9, x FOR PEER REVIEW 11 of 23 
 
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0
 
0.0
4
0.1
3
0.2
3
0.3
2
0.4
1
0.5
1
0.6
0
0.6
9
0.7
9
0.8
8
0.9
7
1.0
7
1.1
6
1.2
5
1.3
5
1.4
4
1.5
3
1.6
3
1.7
2
1.8
1
1.9
00
20
40
60
80
100
120
 
0 10 20 30 40 50 60 70 80 90 100
 
3.3
3
7.7
5
12
.18
16
.60
21
.02
25
.44
29
.86
34
.28
38
.70
43
.12
47
.54
51
.96
56
.38
60
.80
65
.23
69
.65
74
.07
78
.49
82
.91
87
.33
91
.75
0
20
40
60
80
100
120
 
0 20 40 60 80 10
0
12
0
14
0
16
0
18
0
20
0
22
0
24
0
26
0
28
0
30
0
32
0
34
0
36
0
38
0
 
7.0
5
25
.01
42
.97
60
.93
78
.89
96
.85
11
4.8
1
13
2.7
7
15
0.7
3
16
8.6
9
18
6.6
5
20
4.6
1
22
2.5
7
24
0.5
3
25
8.4
9
27
6.4
5
29
4.4
1
31
2.3
7
33
0.3
3
34
8.2
9
36
6.2
50
20
40
60
80
100
120
140
160
 
Figure 6. Box plots (90% confidence interval) and graphic distribution of metabolites with (A) low 
(5-HT, median 0.492 μM), (B) medium (XA, median 5.424 μM) and (C) high median (TRP, median 
64.02 μM) levels quantified in urine in the DONALD study (n = 672). 
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highlighted that the second transition of the TRP 13C-isotope shares the same MRM transition as XA 
(206.09 > 132.01), interfering with its quantification [51]. With our experimental setup, XA 
quantification was achieved by MRM transition (206.09 > 160.01) while the MRM (206.09 > 132.01) 
was used for qualitative purposes. Furthermore, the two peaks were chromatographically 
sufficiently separated, having TRP and XA RT of 4.94 and 5.03 min respectively. The MRM transition 
(206.09 > 160.01) was also common to ILA (RT: 6.96 min) and 5-methoxyindole-acetic acid 
(5-ME-IAA) (RT: 7.35 min), but the three molecules were well separated. 
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Table 2. Metabolite concentration ranges (µM) detected in plasma and urine. n.d.: not detected; n.a.:
data not available.
Plasma (µM) Urine (µM)
Metabolite Min Median Max Min Median Max
l-valine 12.09 62.12 130 1.678 29.15 94.71
picolinic acid 0.00179 0.0198 0.057 0.649 1.402 2.488
dopamine 0 0.0128 0.0718 0.29 2.089 8.029
methionine 3.09 11.45 25.10 0 2.158 36.23
2-aminophenol n.d. n.d.
quinolinic acid 0.414 1.404 9.694 10.58 40.16 146
3-hydroxykynurenine n.d. 0 0.357 3.870
tyrosine 6.721 27.86 71.30 6.013 136 849
l-isoleucine 4.924 26.46 77.95 0.106 12.69 55.82
tyramine n.d. 0.197 4.518 139
l-leucine 10.71 57.07 120.0 1.763 33.05 158
serotonin 0 0.167 1.047 0.04 0.492 1.905
5-hydroxy-tryptophan n.d. 0.0394 0.151 0.723
3-methoxy-p-tyramine n.d. 0.0846 0.346 1.722
kynurenine 0.450 1.270 3.479 0.215 3.703 43.88
dl-phenylalanine 8.096 27.86 71.30 2.342 18.08 107
3-hydroxyanthranilic acid 0.177 0.203 0.322 0.0808 0.412 4.494
tryptophan 8.499 29.82 81.49 7.051 64.02 366
1-acetylisatin n.d. n.d.
3,4-dihydroxyphenyl acetic acid 0 0.0477 73.7 n.d.
xanthurenic acid 0.02 0.0661 0.183 0.561 5.424 36.10
kynurenic acid 0.00553 0.0185 0.167 3.334 20.38 91.75
tryptamine n.d. 0.0272 0.449 2.467
5-methoxytryptamine n.d. n.d.
5-hydroxyindole acetic acid 0.0164 0.0447 0.456 0.0268 19.68 89.54
N-acetyl-5-hydroxytryptamine n.d. n.d.
tryptophan methyl ester n.d. n.d.
homovanillic acid 0.0118 0.0782 1.0 9.313 35.58 136
indoxyl sulfate 0.0491 2.744 12.99 n.a.
indole-3-acetamide n.d. 0.0170 0.272 10.07
anthranilic acid n.d. 0.0950 0.401 2.058
indole-3-lactic acid 0.0759 0.697 4.009 0.198 1.165 18.90
indole-3-carboxylic acid n.d. 0.0305 0.0994 7.279
melatonin n.d. n.d.
5-methoxyindole acetic acid n.d. n.d.
indole-3-carboxaldehyde 0.0103 0.0494 0.186 0.00245 0.123 3.992
indole-3-acetonitrile 0.326 2.003 31.72 3.116 15.60 96.82
indole-3-acetic acid 0.292 1.51 23.01 6.114 30.09 205
indole-3-propionic acid 0 1.156 12.75 0.0187 0.0557 2.197
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3. Discussion
3.1. Optimisation of MS Parameters and Analytical Specificity
The selection of Q and q ions was based on signal intensity, with Q ions being the most intense.
In order to increase MS settling time, we selected just one qualifier ion per molecule and tried to
avoid MRM transitions common to many metabolites when possible. Recently, Whiley et al. (2019)
highlighted that the second transition of the TRP 13C-isotope shares the same MRM transition as XA
(206.09 > 132.01), interfering with its quantification [51]. With our experimental setup, XA quantification
was achieved by MRM transition (206.09 > 160.01) while the MRM (206.09 > 132.01) was used for
qualitative purposes. Furthermore, the two peaks were chromatographically sufficiently separated,
having TRP and XA RT of 4.94 and 5.03 min respectively. The MRM transition (206.09 > 160.01) was
also common to ILA (RT: 6.96 min) and 5-methoxyindole-acetic acid (5-ME-IAA) (RT: 7.35 min), but the
three molecules were well separated.
Similarly, N-acetyl-5-hydroxytryptamine (NA-5-HT) and the TRPME had the same MRM for
quantification (219.2 > 160.0), but the two peaks were baseline separated, having an RT of 5.86 and
6.07 min respectively.
All the tested compounds except DOPAC and HVA contained nitrogen atoms and were easily
detected as [M+H]+ in positive ion mode. IS contains both a nitrogen atom and a sulfate group, but a
better response is obtained in negative ion mode. Therefore DOPAC, HVA and IS were detected as
[M–H]-, by setting up polar switching within the chromatographic run.
Calibration accuracy was obtained with the use of 8 deuterated standards (Table 1). Since
deuterated internal standards were not available for all the tested metabolites, and in order to limit the
cost of the calibration, we opted for a) chemically related molecules (i.e., TYR-d4 for PHE, TRP-d5 for
indole derivatives and DOPAC-d5 for HVA in negative ion mode) and b) molecules eluting nearby
(i.e., MET-d4 for BCAAs).
3.2. Choice of Chromatographic Technique
Two analytical approaches were initially tested, based on Reversed-Phase (RP) chromatography on
a Waters ACQUITY BEH C18 1.7µm, 2.1× 150 mm, and Hydrophilic Interaction Liquid Chromatography
(HILIC) using a Waters ACQUITY BEH AMIDE 1.7 µm, 2.1 × 150 mm. HILIC was tested due to the
high polarity of certain metabolites, such as GABA, VAL, ILE, LEU, TYR, MET, DA, among others.
This column is widely considered to be suitable for the analysis of several other polar metabolites [52].
This column provided excellent efficiency and chromatographic resolution for separation of most polar
compounds, but indole derivatives were poorly retained, hampering their separation and quantification
(see Figure S1 for details).
HILIC RT stability was affected by slight pH modification and we noticed that RT shifts could appear
during long acquisition sequences. Nevertheless, ammonium formate, present in both mobile phases,
tends to stick on the orifice plate after desolvation, which increases the chance of source contamination
and ion suppression. All these considerations made HILIC relatively less attractive for the analysis of
TRP-derived metabolites in a large number of biological samples. At this point, RP chromatography
was selected for further method optimisation and HILIC remained as a complementary tool for the
separation of highly hydrophilic compounds.
3.3. Optimisation of Chromatography on C18 Stationary Phase
Five different RP columns were tested using different elution programs: Waters ACQUITY BEH
C18 1.7 µm, 2.1 × 150 mm; Waters ACQUITY HSST3 1.8 µm, 2.1 × 150 mm; Waters Cortecs UPLC C18
1.6 µm, 2.1 × 100 mm; Phenomenex Kinetex Polar C18 2.6 µm, 2.1 × 100 mm; and Phenomenex Kinetex
EVO C18 2.6 µm, 2.1 × 100 mm (see Figure S2 for details).
Most polar compounds were poorly retained on 100 mm columns, even if the percentage of aqueous
solvent was increased to 100%; therefore, these columns were not selected for further optimisation.
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150 mm columns demonstrated the same separation efficiency, but the Waters HSST3 column was
selected given that a) polar compounds are better retained, b) the critical couple of analytes ILE (RT:
2.25 min) and LEU (RT: 2.38 min) are baseline separated (Figure 2, panels A and B).
3.4. Comparison of Proposed Extraction Procedures and Analytical Performance: Efficiency and Efficacy
The efficiency and efficacy of Ostro 96-well plate and Liquid-Liquid Extraction (LLE) methods
were first evaluated for an initial set of 21 key metabolites in plasma, by studying recovery and relative
standard deviations (RSDs) (Table 3). The Ostro 96-well plate rapidly extracted and precipitated
proteins using ice-cold ACN, containing 1% FA. To improve metabolite recovery, plates were shaken
twice for 10 min before filtering; different ratios of water: ACN (1:1, v/v, 8:2, v/v and pure ACN),
and the addition of FA were also tested as reconstitution solvents. According to the manufacturer’s
procedures, a mixture of water and MeOH were used to recover extracted metabolites. In our case,
MeOH was replaced by ACN in order to a) increase retention and b) increase the selectivity and peak
shapes of more polar compounds, especially those eluting in the first 3 min of the chromatographic run.
Ultimately, water: ACN (8:2, v/v) 0.1% FA was a good compromise for metabolite recovery, peak shape
and chromatographic selectivity. On the other hand, urine samples were simply diluted and filtered.
In this context, the dilution factor was first studied. Urine samples were diluted five- and ten-fold in
water with 0.1% FA. Five-fold dilution enabled the detection of metabolites present in low amounts as
DA, but those present at high levels could saturate the detector, hampering quantification. Ten-fold
dilution avoided detector saturation, while at the same time the presence of more water in the sample
improved the retention of polar compounds and peak shapes.
Table 3. Recovery obtained from analysis of 21 pre-selected metabolites using LLE or Ostro 96-well plate.
The selected metabolites were: GABA, 2-AM, VAL, MET, ILE, LEU, DA, 5-HT, PHE, TYR, 3-ME-TYRA,
TRP, AA, 1-acetylisatin, 3-OH-AA, IACN, IAA, KA, XA, NA-5-HT, 5-OH-TRP and alpha-chloralose.
Recovery (Average = 5) Extraction Methods
21 pre-selected metabolites LLE Ostro 96-Well plate
<50 1 1
50–60 1 1
60–70 5 0
70–80 3 1
80–90 4 1
90–100 3 15
>100 4 2
LLE and Ostro 96-well plate methods were compared in terms of plasma recovery (Table 3). In this
table, LLE and Ostro 96-well plate showed a suitable range of recovery, which in the vast majority
of cases was over 60%. However, the LLE method showed relatively lower recovery rates compared
to Ostro 96 well plate, ranging from 50% to 90%. Recovery was over 75% for LEU, ILE and VAL.
By contrast, 5-OH-TRP and KA did not reach 65% recovery, and XA showed the lowest recovery.
On the other hand, Ostro 96-well plate was able to adequately extract the selected metabolites, with 15
metabolites ranging from 90-100%, such as TRP, MET and KYN. More importantly, the recovery
obtained was in an acceptable range and RSDs were below 20%. To sum up, data comparison
showed that the Ostro 96-well plate method offered an appropriate range of recovery and low RSDs
compared with LLE. It should be noted that this method is supposed to be routinely used within the
HEALTHMARK project and thousands of samples from several clinical studies would be analysed.
Therefore, in addition to the standard parameters required for a new method (sufficiently innovative
and robust compared to other available methods for the intended application), here reproducibility,
speed and accurate quantification are strongly required. For these reasons, the Ostro 96-well plate
method was selected, since it was the most efficient and effective extraction procedure evaluated.
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The combination of sample preparation with an Ostro 96-well plate and UHPLC separation with C18
stationary phase was selected for further studies in order to extend the number of metabolites and
validate the method.
3.5. Method Validation
The following parameters were studied for 40 metabolites related to TRP and TYR metabolism
and BCAAs: linearity, LOQ, recovery, precision as repeatability and within-lab reproducibility, process
efficiency and ME. Calibration curves were designed independently for plasma and urine to cover
the expected metabolite concentration range according to available data, and changed accordingly
after the analysis of biological samples, in order to precisely define the typical working range for
each metabolite.
Linear dynamic ranges for both plasma and urine were acceptable, as the correlation coefficient
was always adequate (r2 > 0.990). For low level metabolites, the LOQ was in the range of a few ng/Ml
for both matrices, except for some compounds that behaved differently. As an example, 2-AM had
a LOQ of 3.9 ng/mL in urine, while in plasma it went up to 78.1 ng/mL. For high level metabolites
(BCAAs, TRP, TYR and PHE), it is not necessary to achieve an LOQ of few ng/mL and the value was
set as the lowest calibration point falling within the linear range.
The use of Ostro 96-well plates with modifications enabled us to achieve satisfactory recovery,
over 85% in plasma and 80% in urine spiked at low concentration. Similarly, accuracy at medium
spiked concentration was excellent for both matrices, with CV being below 15%.
Several metabolites saw a decrease in recovery and poorer accuracy at low spiked concentration;
this was due to the fact that spiked amounts were close to the LOQ, and analytical error may therefore
be greater. The quantification of GABA was significantly deviated in both matrices. This is because
GABA was not retained with our experimental setup and eluted with the chromatographic front.
We propose using data on GABA to detect fold changes rather than to provide absolute
quantification. For better quantification of most polar metabolites, HILIC may still represent an
appropriate method. The presence of co-eluting compounds may affect the ionization of the targeted
metabolites producing ME. In this research, ME was negligible for most metabolites, ranging between
80–120% in both plasma and urine. Ion suppression by matrix components significantly affected
quantification for VAL, DA, MET, QA and LEU in plasma, together with 2-AM and TYRA in urine. These
metabolites are the most polar of those tested and were eluted at the beginning of the chromatographic
run, before 2.5 min. Several attempts were made to improve chromatographic separation and MS
response. For example, starting with 100% mobile phase A or keeping it isocratically at 95%A for
a few minutes increased retention, but the peak shapes got worse, hampering integration and thus
quantification. Phospholipids were efficiently removed from plasma by Ostro 96-well plates, while no
significant effects were detected in urine.
Removal of matrix contaminant, together with splitting of the UHPLC flow to waste during
non-acquisition time, along with good column cleaning, enabled us to acquire up to 300 samples per
batch without any significant shift in RT and alteration in the MS response. This is very important in
clinical applications, where simultaneous analysis of a large number of samples in the lowest number
of separate batches is desirable.
3.6. Method Application
The availability of a large number of samples both for plasma (Rhineland Study) and urine
(DONALD Study) allowed us to monitor the typical range of presence for each of these metabolites
in two independent German populations. The method allowed the quantification of 24 out of
39 metabolites in plasma and 30 metabolites in urine (Table 2). In general, the results were in agreement
with published results, despite some biological variation (Table S4).
This information is relevant for the analyst, since it allowed us to verify that the method allows
quantitative analysis of 39 out of the 40 target metabolites (all of them except GABA). More detailed
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analysis of multiple factors of variability influencing the concentration of these compounds is outside
the scope of this paper and will be the subject of other publications.
3.7. Study Strengths and Limitations
Most of the studies available in the literature cover a limited number of metabolites related to
TRP, TYR, BCAAs and gut-derived metabolites [49–51]. To achieve a full understanding of microbial
metabolite–host interaction in homeostasis and diseases, we validated an analytical method for the
separation and detection of 39 metabolites, targeting key branches of different metabolic pathways
simultaneously, in particular those related to the microbiota-gut-brain axis [10], covering the different
forms of TRP usage, simultaneously investigating serotonergic metabolism [25] and KP metabolism [22].
Our quantitative results suggest that the method is suitable for high-throughput applications
in clinical studies, covering an unprecedented number of crucial metabolites in a single analysis.
It represents the starting point for future research, and other metabolites of interest can be inserted
as required.
The method was designed for low sample requirements, minimal sample handling and working
steps, fast extraction, high sample throughput and fast instrumental analysis of 14 min per sample.
Up to 384 samples (4 well plates) can be extracted by a single operator per day, and up to 96 samples
can be acquired per day.
The method was independently validated on plasma and urine, in order to support
multi-compartment studies, allowing direct comparison of metabolite concentrations in both biofluids.
One limitation of this study relates to pre-analytical sample management, from sample collection
to handling and storage, which can affect sample quality. This issue was outside the scope of this
work, but we are aware it is important for the final results [53–57]. For example, accurate measurement
of 5-HT in the whole blood sample is affected by 5-HT instability and reflects platelet 5-HT [58–60];
inappropriate blood sample handling can lead to inaccurate results. To avoid these problems, we relied
on standard laboratory practices to prepare samples, such as those highlighted in [57]. In this particular
case, we selected fasting plasma; EDTA blood was collected and centrifuged within 10 min of collection,
and aliquoted and stored at −80 ◦C within 2 h of collection. EDTA is commonly used as anticoagulants
for the generation of platelet-free plasma [61].
Urine was collected as 24-h samples in order to obtain an overall picture of an individual’s
metabolic excretion and to eliminate the wide variability observed for spot urine collection. Urine pH
can affect the final results; to avoid this problem urine pH was checked at sampling (pH range: 4.9-7.9)
and all the samples fell within the desired range [62]. Furthermore, since the samples were stored at
low temperature, urine pH was expected to be stable until the analytical phase [62].
The attention of researchers on complex interactions between gut bacteria and human brain has
increased in recent years [15,16,22,25]. In 2013, the term “psychobiotics” was introduced to define
beneficial bacteria that, when ingested in appropriate quantities (probiotics), exert positive effects
in psychiatric patients by influencing the gut bacteria-brain-relationship [63]. This definition was
then expanded to prebiotics, food components that support growth of intrinsic commensal bacteria,
but this concept could be extended to any substance that “exerts a microbiome-mediated psychological
effect” [64]. The psychobiotics treatment could be an interesting strategy to improve life of people
suffering from psychiatric disorders but further studies are needed to facilitate its development [64,65];
our validated method can be a complementary tool to evaluate the direct effect of psychobiotics on
TRP, TYR, BCAA and gut-derived metabolites.
4. Materials and Methods
4.1. Reagents and Chemicals
Gamma-aminobutyric acid (HMDB0000112), tryptamine (HMDB0000303) and l-tyrosine
(HMDB0000158) were purchased from Fluka (Milan, Italy); 2-aminophenol (ChemSpider ID 5596;
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PubCHem CID 5801), 3,4-dihydroxyphenyl acetic acid (HMDB0001336), 3,4-dihydroxyphenyl acetic
acid-d5, 3-hydroxykynurenine (HMDB0011631), 5-methoxyindole-3-acetic acid (HMDB0004096),
5-methoxytryptamine (HMDB0004095), indole-3-acetic acid (HMDB0000197), indole-3-carboxaldehyde
(HMDB0029737), indole-3-carboxylic acid (HMDB0003320), indole-3-lactic acid (HMDB0000671),
indole-3-propionic acid (HMDB0002302), indoxyl sulfate (HMDB0000682), kynurenine (HMDB0000684),
melatonin (HMDB0001389), dl-phenylalanine (HMDB0000159), picolinic acid (HMDB0002243),
tryptophan methyl ester (ChemSpider ID 70366, PubCHem CID 77980) and tyramine
(HMDB0000306) were purchased from Sigma (Milan, Italy); 1-acetylisatin (ChemSpider ID
10845, PubCHem CID 11321), 3-hydroxyanthranilic acid (HMDB0001476), 3-methoxy-p-tyramine
(HMDB0000022), 5-hydroxyindole-3-acetic acid (HMDB0000763), 5-hydroxyindole-3-acetic
acid-d5, 5-hydroxy-tryptophan (HMDB0000472), anthranilic acid (HMDB0001123), dopamine
(HMDB0000073), dopamine-d4, homovanillic acid (HMDB0000118), indole-3-acetamide
(HMDB0029739), indole-3-acetonitrile (HMDB0006524), kynurenic acid (HMDB0000715), kynurenic
acid-d5, l-isoleucine (HMDB0000172), l-leucine (HMDB0000687), l-valine (HMDB0000883), methionine
(HMDB0000696), methionine-d4, N-acetyl-5-hydroxytryptamine (HMDB0001238), quinolinic acid
(HMDB0000232), serotonin (HMDB0000259), serotonin-d4. l-tryptophan (HMDB0000929),
l-trypophan-d5, l-tyrosine-d4 and xanthurenic acid (HMDB0000881) were purchased from Spectra
2000 (Rome, Italy). Human citrated plasma was obtained from Sigma (Milan, Italy).
LC-MS grade acetonitrile (ACN), methanol (MeOH) and 2-propanol were purchased from
Honeywell (Monza, Italy), LC-MS grade FA was purchased from Sigma (Milan, Italy). Ultrapure
Milli-Q deionized water was obtained from Elix (Merck-Millipore, Milan, Italy). OSTRO 96-well plates
(25 mg) were purchased from Waters (Milan, Italy). Human plasma was purchased from Sigma Aldrich
(Milan, Italy).
4.2. Preparation of Stock Solution and Calibration Curves
Stock solutions (1000 mg/mL) were prepared by dissolving each standard in methanol except TYR,
TYR-d4 and 3-OH-KYN, which were dissolved in 1 M HCl, KA-d5 in MeOH: DMSO 1:1 (v/v) and XA
in DMSO. The concentration ranges are reported in Table S3.
4.3. Method Validation
4.3.1. Linearity and LOQs
Calibration standards were evaluated at 14 concentration levels, prepared with serial dilution in
water with 0.1% FA. A linear polynomial model was employed with 1/X weighting factor. The method
was considered linear in a specific concentration range if the correlation coefficient (2) was equal to or
greater than 0.990. The calibration range was designed according to data available in literature, public
databases (www.hmdbr.ca) and from analysis of real plasma and urine samples. LOQs were calculated
by estimating the calibration points with a signal-to-noise ratio (S/N) of 10.
4.3.2. Recovery, Intra- and Inter-Day Accuracy and Precision, and RT Stability
Analytical recovery was assessed by spiking standards in plasma and urine at low, medium
and high concentrations according to the calibration ranges described above. The low and high
concentration were set as 5-fold lower or higher than the medium values. As both matrices contained
tested metabolites at a different concentration, the spiked concentration was calculated as the % of
metabolite recovered compared to the spiked concentration after subtracting the average response
from the blank (unspiked) sample. Calibration curves in water with 0.1% FA were used for recovery
determination. See Tables S1 and S2 for further details.
Intra-day repeatability was assessed by analysing samples (n = 5) spiked at low, medium and
high concentration for both plasma and urine within one day. Inter-day repeatability was assessed
by analysing QC (n = 5), analysed on three separate days (1, 3 and 5). Precision is expressed as
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the coefficient of the variation percentage (CV%) estimated for spiked QC, after subtracting the
concentration of unspiked samples. For acceptance, CV was required to be within 15% at the medium
and high concentration and within 20% at the low concentration.
4.3.3. RT Stability
RT stability was assessed by analysis of metabolites detected in 1000 plasma and 672 urine samples.
For metabolites not detected in biological samples, the RT was obtained from analysis of QC spiked at
medium standard concentration.
4.3.4. Analysis of Blank Samples and ME
Urine blanks (5X) were prepared as described in paragraph 4.4.1 by diluting 25 µL of sample in
225 µL of water with 0.1% FA. Plasma blanks (5X) were prepared as described in paragraph 4.4.1.2 by
adding 20 µL of ACN 1% FA to 50 µL plasma instead of standard mix.
MEs were evaluated using a MMC approach. Solvent calibration slopes (SC) were compared
with those obtained by fortifying the biological fluids and the deviation was calculated as follows:
% of variation = (MMC slope/SC slope) × 100. For plasma, 50 µL of sample and 20 µL of ACN 1%
FA (MMC) were loaded into Ostro 96-well plates and extracted as described below. Dried samples
were reconstituted in 100 µL of water/ACN (8:2, v/v), 0.1% FA at appropriate concentration levels.
For urine, 25 µL of deionized water (SC) or urine (MMC) were diluted with 225 µL 0.1% FA spiked at
appropriate levels.
4.3.5. Carryover Effect and Phospholipid Removal
The carryover effect was assessed by injecting neat ACN after the highest calibration points of SC
and MMC and after the acquisition of each recovery batch.
Plasma clean up from phospholipids was addressed by performing a PIS in positive ion mode at
m/z 184.03 (protonated phosphocholine), which is specific for PC and SM. 50 µL of plasma were directly
mixed with 50 µL of water: ACN 8:2 (v/v), 0.1% FA in order to achieve the same dilution obtained after
plasma extraction on Ostro 96-well plates. For urine, the comparison was conducted with undiluted
and 10-fold diluted urine.
4.4. Extraction Procedures
4.4.1. Urine
Urine was thawed on ice and 25 µl aliquots were loaded into 96-well multifilter plates (Millipore)
together with 225 µl of internal standard mix (500 ng/mL) in water with 0.1% FA. 96-well plates were
shaken on a vortex for 15 sec, and subsequently filtered using a positive pressure-96 manifold (Waters).
Samples were collected in 350 µL 96-well plates and kept at −80 ◦C until analysis.
Plasma
Plasma aliquots (50 µL) were loaded onto an Ostro 96-well plate (Waters, Milan, Italy) and 20 µL
of internal standard mix in ACN 1% FA (500 ng/mL) were added. Protein precipitation and metabolite
extraction were performed by adding 150 µL of ice-cold ACN 1% FA. Plates were covered, vortexed for
15 sec and placed on an Eppendorf shaker for 10 min at 500 rpm (Eppendorf, Milan, Italy), then filtered
using a positive pressure-96 manifold (Waters). The extraction procedure was repeated by adding
150 µL of ice-cold ACN 1% FA. Extracts were brought to dryness with a gentle stream of nitrogen at
37 ◦C using a Techne Dr-block DB 3D heater, re-dissolved in 100 µl of water: ACN 8:2 0.1 % FA and
transferred into 350 µL 96-well plates, kept at −80 ◦C until analysis.
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LLE of Urine and Plasma
100 uL of plasma or urine were extracted using 200 uL of ice-cold ACN containing internal
standards. The mixtures were first shacked for 30 min at 500 rpm (5 ◦C). Then, mixtures were stored 1 h
at −20 ◦C to improve protein precipitation and then centrifuged at 17,968 g (14000 rpm) for 15 min at
4 ◦C. Afterwards, the supernatants were collected and stored at −80 ◦C until analysis. The supernatants
were directly injected.
4.5. Ultra High Performance Liquid Chromatography-Electrospray Ionization-Triple Quadrupole-Mass
Spectrometry (UHPLC-ESI-QqQ-MS)
Detection was performed on a Waters® Xevo TQ MS Triple Quadrupole equipped with ESI
source and coupled online with an Aquity UHPLC (Waters, Milford, MA, USA). The MS operated
in positive ionization mode, setting the capillary at 270 ◦C, the source at 300 ◦C and source voltage
at 3 kV. Detection of IS, DOPAC, DOPAC-d5 and HVA were performed in negative ion mode in the
same run by setting polarity switching. Ultra-high purity argon was used as collision gas. MS and
MS/MS conditions were optimised via software (Intellistart, Waters, Milford, MA, USA) by infusing
analytical standards.
4.5.1. RP C18 Chromatography
Chromatographic separation was performed using a Water UPLC HSST3 (1.8 µm, 2.1 × 150 mm,
100 A pore diameter) purchased from Waters (Milan, Italy). Mobile phase A was water with 0.1% FA,
B was ACN 0.1% FA. The gradient started with 5% B and was maintained for 0.5 min; then % B was
increased to 10% at 2.5 min, 15% at 3.5 min, 25% at 4.5 min, 35% at 5.5 min, 45% at 6.5 min, 55% at
7 min and then to 100%B at 7.5 min. Final conditions were retained for 3 min and the column was
re-equilibrated to the initial conditions for 4 min. The total run time including column re-equilibration
was 14 min. The flow rate was 0.3 mL/min, the injection volume was 2 µL and the column oven was
set at 40 ◦C. The weak and strong solvent washes were water: MeOH (9:1, v/v) and water: ACN:
MeOH: 2-propanol (1:1:1:1, v/v/v/v) respectively. Data were acquired and processed with Mass Lynx 4.1
software (Waters).
4.5.2. HILIC Chromatography
A Waters ACQUITY BEH AMIDE 1.7 µm, 2.1 x 150 mm analytical column was used. The mobile
phases consisted of (A) 10 mM ammonium formate and 0.2% FA in water: ACN (1:1, v/v), and (B)
10 mM ammonium formate and 0.2% FA in water: ACN (5:95, v/v). A multi-step elution gradient was
developed as follows, at a flow rate of 0.5 mL/min: at 0.0 min, 100% B a gradient up to 4.0 min, 90% B;
then %B was decreased to 70% at 8.0 min, 60% at min 9.0, 50% at min 9.5 and maintained isocratically
until min 11.0. Lastly, a reconditioning period up to 1.5 min at 100% B was used. The sample injection
volume was 5 µL and the autosampler temperature was kept at 5 ◦C. The weak and strong solvent
washes were water: ACN: MeOH: 2-propanol (1:1:1:1, v/v/v/v) and water: MeOH (9:1, v/v) respectively.
4.6. Method Application to Biological Samples
This analysis was carried out as part of the European Joint Programming Initiative, “A Healthy Diet
for a Healthy Life” Metabolic HEALTH through Nutrition, Microbiota and Tryptophan bioMARKers
(HEALTHMARK) project. The project aims to investigate the complex associations between microbiota
and microbiota-derived bioactives of the TRP metabolism, diet and metabolic health. The applicability
of the method was assessed by analysis of 24-h urine (n = 672, mean age of 16 years with 50.5% males
and 49.5% females) collected within the DONALD study and of plasma samples (n = 1000) obtained
from adults (age ≥ 30 years) collected within the Rhineland study. Data were analysed using Statistica
v. 13.3 (TIBCO Software Inc., Palo Alto, CA, USA).
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4.6.1. The DONALD Study
The DONALD study is an ongoing, open cohort study conducted in Dortmund, Germany by the
Unit of Nutritional Epidemiology, Department of Nutrition and Food Sciences, University of Bonn,
Bonn, Germany. This study has collected data on the diet, growth, development and metabolism of
apparently healthy children and adolescents since 1985. Children are enrolled at 3 months of age.
The collection of 24-h urine samples is part of the annual assessments as soon as the children can
provide the samples. The pre-analytical urine pH range was between 4.9 and 7.9, therefore suitable for
metabolite quantification [62]. All samples were stored at −22 ◦C without the addition of preservatives
or chemicals and then at −80 ◦C until laboratory analysis. Further details on the DONALD study [66]
and urine collection and storage [67] have been described elsewhere. The DONALD study was
approved by the Ethics Committee of the University of Bonn according to the guidelines of the
Declaration of Helsinki (approval number 098/06). Written consent was obtained from parents and
later on from study participants.
4.6.2. The Rhineland Study
The Rhineland Study is an ongoing community-based cohort study in which all inhabitants of
two geographically defined areas in the city of Bonn, Germany aged 30–100 years are being invited
to participate. Persons living in these areas are predominantly German with Caucasian ethnicity.
Participation in the study is possible by invitation only. The only exclusion criterion is insufficient
German language skills to give informed consent. Approval to undertake the study was obtained
from the ethics committee of the University of Bonn, Medical Faculty (approval number 338/15).
All participants gave written informed consent.
Fasting blood was collected from all participants between 7:00 and 9:30 am, including 2 × 10 mL
EDTA blood (EDTA Vacutainer K2), an anticoagulant commonly used for the generation of platelet-free
plasma. Plasma is centrifuged for 10 min at 2000× g at 20 ◦C within 10 min of blood collection;
centrifuge brake is set on off to avoid platelet activation. Automated aliquoting of the plasma takes
place within less than 35 min after centrifugation into 500 µL aliquots (Hamilton Microlab Star).
All aliquots are directly cooled (10 ◦C) during the process and are placed into a chest freezer (−80 ◦C)
within less than 45 min after aliquoting. Time points of blood withdrawal, centrifugation, aliquoting
and freezing time are documented in the laboratory information management system (LIMS).
5. Conclusions
A UHPLC-ESI-QqQ-MS method was developed for high-throughput, accurate quantification of
39 metabolites related to TRP, TYR, BCAAs and several gut-derived metabolites. The inclusion of
a large number of known metabolites, whose concentration is driven by microbial metabolite–host
interaction, provided a new metabolomic profiling method suitable for supporting clinical investigation
of several important biological questions and opening up new possibilities for nutritional studies
aimed at understanding and preventing disease.
Metabolite extraction from plasma was designed on Ostro 96-well plates in order to ensure
protein precipitation, lipid removal and good metabolite recovery. For urine, we opted for filtration
and 10-fold dilution in order to ensure the simultaneous analysis of metabolites present in different
concentration ranges.
The new method was then tested on a large number of real human plasma and urine samples
obtained from two main observational and epidemiological studies across the lifespan. This allowed us
to estimate the typical working concentration range for each analyte, and to verify that application of
the method to real samples representative of Central Europe subpopulations falls within the validation
conditions of the method.
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